Treatment of acute gout: A systematic review

• Published in: Seminars in arthritis and rheumatism 2014-08, Vol.44 (1), p.31-38
• Main Authors: Khanna, Puja P., MD, MPH, Gladue, Heather S., DO, Singh, Manjit K., MD, FitzGerald, John D., MD, PhD, Bae, Sangmee, MD, Prakash, Shraddha, MD, Kaldas, Marian, MD, Gogia, Maneesh, MD, Berrocal, Veronica, PhD, Townsend, Whitney, MLIS, Terkeltaub, Robert, MD, Khanna, Dinesh, MD, MS
• Format: Article
• Language: English
• Subjects: Acute Disease; Acute gout; Adrenal Cortex Hormones - therapeutic use; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Arthritis, Gouty - drug therapy; Colchicine - therapeutic use; Cyclooxygenase 2 Inhibitors - therapeutic use; Gout - drug therapy; Gout Suppressants - therapeutic use; Humans; Hyperuricemia - drug therapy; Rheumatology; Systematic review; Treatment Outcome
• ISSN: 0049-0172; 1532-866X
• DOI: 10.1016/j.semarthrit.2014.02.003

Abstract Objective Acute gout is traditionally treated with NSAIDs, corticosteroids, and colchicine; however, subjects have multiple comorbidities that limit the use of some conventional therapies. We systematically reviewed the published data on the pharmacologic and non-pharmacologic agents used for the treatment of acute gouty arthritis. Methods A systematic search was performed using PubMed and Cochrane database through May 2013. We included only randomized controlled trials (RCTs) that included NSAIDs, corticosteroids, colchicine, adrenocorticotropic hormone (ACTH), interleukin-1 (IL-1) inhibitors, topical ice, or herbal supplements. Results Thirty articles were selected for systematic review. The results show that NSAIDs and COX-2 inhibitors are effective agents for the treatment of acute gout attacks. Systemic corticosteroids have similar efficacy to therapeutic doses of NSAIDs, with studies supporting oral and intramuscular use. ACTH is suggested to be efficacious in acute gout. Oral colchicine demonstrated to be effective, with low-dose colchicine demonstrating a comparable tolerability profile as placebo and a significantly lower side effect profile to high-dose colchicine. The IL-1β inhibitory antibody, canakinumab, was effective for the treatment of acute attacks in subjects refractory to and in those with contraindications to NSAIDs and/or colchicine. However, rilonacept was demonstrated to be not as effective, and there are no RCTs for the use of anakinra. Conclusion NSAIDs, COX-2 selective inhibitors, corticosteroids, colchicine, ACTH, and canakinumab have evidence to suggest efficacy in treatment of acute gout.